Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 50.44

From 52W high−36.74%

Volume3.17M

Market capCNY 6.92B

P/E (TTM)31.5x

P/S (TTM)5.6x

Div yield0.97%

Key dataSep 18, 2026

Open

CNY 50.44

From 52W high

−36.74%

Volume

3.17M

Market cap

CNY 6.92B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

17.8x

P/E (TTM)

31.5x

RSI (14)

53.4

MomentumView details →

1D Return

−5.72%

YTD Return

−28.66%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

31.5x

EV/EBITDA

17.8x

EV/Sales

5.2x

P/S (TTM)

5.6x

P/B (TTM)

1.9x

ProfitabilityView details →

Gross Margin

91.61%

Net Margin

18.89%

EBITDA Margin

29.04%

ROE (TTM)

6.36%

ROA (TTM)

5.80%

Asset Turnover

0.30x

GrowthView details →

Revenue YoY

−4.68%

EPS YoY

−14.40%

FCF YoY

+10.10%

Revenue CAGR 3Y

−6.96%

EPS CAGR 3Y

−27.63%

EBITDA YoY

—

MomentumView details →

1D Return

−5.72%

YTD Return

−28.66%

1Y Return

−32.46%

RSI (14)

53.4

vs 50D SMA

+4.82%

vs 200D SMA

−12.57%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

7.89x

Quick Ratio

7.40x

Div Yield

0.97%

Div Rate

CNY 0.50

Div Growth 1Y

−50.00%

EarningsView details →

EPS (Actual)

CNY 0.88

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

1.20B

Net Income (TTM)

226.55M

Op. CF (TTM)

417.27M

Next earningsOct 27, 2026 →

Latest newsMore news →

Kanghua Biological announced its first-half 2026 results: revenue of 538 million yuan, up 11.25% year-on-year; net profit attributable to shareholders of 141 million yuan, up 23.25% year-on-year; non-recurring-adjusted net profit of 134 million yuan, up 20.28% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.35d ago

Kanghua Biotech announced that its external investment and related-party transaction proposal was approved at an extraordinary shareholders' meeting, planning to subscribe in installments to Namixin's newly increased registered capital and acquire equity, holding 100% of Namixin after completion; recently Namixin completed the first-phase industrial and commercial change registration with a registered capital of 27.17 million yuan.49d ago

Similar companies

长高电气002452.SZ 元力股份300174.SZ 理邦仪器300206.SZ 华源控股002787.SZ 雷电微力301050.SZ 欢乐家300997.SZ Find similar companies →

Latest newsMore news →

Kanghua Biological announced its first-half 2026 results: revenue of 538 million yuan, up 11.25% year-on-year; net profit attributable to shareholders of 141 million yuan, up 23.25% year-on-year; non-recurring-adjusted net profit of 134 million yuan, up 20.28% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.35d ago Kanghua Biotech announced that its external investment and related-party transaction proposal was approved at an extraordinary shareholders' meeting, planning to subscribe in installments to Namixin's newly increased registered capital and acquire equity, holding 100% of Namixin after completion; recently Namixin completed the first-phase industrial and commercial change registration with a registered capital of 27.17 million yuan.49d ago